Biosimilar Litigation Settlement Score Card: Genentech-Pfizer Herceptin Agreement Is 10th Deal
Genentech inks second settlement of trastuzumab biosimilar litigation; suits ongoing against Amgen, Celltrion/Teva, and Samsung with joint claim construction proceedings.
You may also be interested in...
Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US
Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.
FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar
Amgen and Allergan’s biosimilar version of Herceptin has been approved by the US Food and Drug Administration.
Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
The latest drug development news and highlights from our US FDA Performance Tracker.